Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Kairos Pharma (KAPA) Operating Income (2023 - 2025)

Kairos Pharma filings provide 2 years of Operating Income readings, the most recent being -$1.5 million for Q2 2025.

  • On a quarterly basis, Operating Income fell 555.86% to -$1.5 million in Q2 2025 year-over-year; TTM through Jun 2025 was -$4.6 million, a N/A change, with the full-year FY2025 number at -$5.6 million, down 137.81% from a year prior.
  • Operating Income hit -$1.5 million in Q2 2025 for Kairos Pharma, down from -$1.3 million in the prior quarter.
  • In the past five years, Operating Income ranged from a high of -$222000.0 in Q2 2024 to a low of -$1.5 million in Q2 2025.